UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
Dated
June
22, 2016
Commission
File Number 001-36421
AURINIA PHARMACEUTICALS INC.
(Exact
name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250)
708-4272
(Address and telephone number of registrant’s
principle executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ⃞ Form 40-F ⊠
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ⃞ No ⊠
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: |
June 22, 2016 |
|||
Aurinia Pharmaceuticals Inc. |
||||
|
||||
|
|
By: |
/s/ Dennis Bourgeault |
|
|
Name: |
Dennis Bourgeault |
||
|
|
Title: |
Chief Financial Officer |
EXHIBIT INDEX
Exhibit |
Description of Exhibit |
|
99.1 |
News Release – Aurinia Announces Closing of US$7 Million Private Placement |
3
Exhibit 99.1
Aurinia Announces Closing of US$7 Million Private Placement
VICTORIA, British Columbia--(BUSINESS WIRE)--June 22, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has completed its previously announced private placement of 3,000,000 units of the Company at US$2.36 per unit for total gross proceeds of US$7,080,000 (the “Private Placement”). Each unit consists of one common share of the Company and a 0.35 of one common share purchase warrant exercisable for a period of two years from the date of issuance at an exercise price of US$2.77. Further information regarding the terms of the private placement and the units issued thereunder can be found in the Company’s press release dated June 15, 2016.
All securities issued pursuant to the Private Placement are subject to a four month-and-one-day hold period in Canada and a six month hold period in the United States in accordance with applicable securities laws. Pursuant to a registration rights agreement entered into with each subscriber, the Company will, within 30 days of closing, file a prospectus supplement under its registration statement on Form F-10 with respect to resales in the United States, from time to time, of the common shares issuable under the Private Placement and the common shares issuable upon the exercise of warrants. Upon filing of the prospectus supplement, the common shares and warrant shares will be freely tradeable in the United States if sold pursuant to the resale registration statement.
Certain insiders participated in the Private Placement. The Private Placement is exempt from the formal valuation and majority of the minority requirements applicable to related party transactions as set out in National Instrument 61-101 Protection of Minority Securityholders in Special Transactions as the aggregate fair market value of the securities purchased by related parties pursuant to the Private Placement is less than 25% of Aurinia’s market capitalization.
Canaccord Genuity Inc. acted as sole placement agent for the Private Placement.
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. The fully-enrolled Phase 2b AURA-LV clinical trial is evaluating the efficacy of its lead drug, voclosporin, as a treatment for active LN. LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
CONTACT:
For More Information:
Aurinia
Pharmaceuticals Inc.
Michael R. Martin, 250-708-4272
Chief
Operating Officer
mmartin@auriniapharma.com
or
Renmark
Financial Communications Inc.
Barry Mire: bmire@renmarkfinancial.com
Laura
Welsh: lwelsh@renmarkfinancial.com
Tel: (416) 644-2020 or
(514) 939-3989